Thr180
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr180  -  P38A (mouse)

Site Information
RHTDDEMtGYVATRW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447970

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 178 , 188 ) , immunoprecipitation ( 4 , 5 , 11 , 13 ) , mass spectrometry ( 2 , 3 , 4 , 6 , 7 , 14 , 15 , 16 , 18 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 44 , 56 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 85 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 135 , 136 , 137 , 140 ) , microscopy-colocalization with upstream kinase ( 143 ) , multiple reaction monitoring (MRM) ( 5 ) , mutation of modification site ( 4 , 153 , 161 , 165 , 169 , 178 , 188 ) , phospho-antibody ( 4 , 5 , 9 , 11 , 12 , 13 , 17 , 19 , 20 , 23 , 42 , 45 , 46 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 57 , 70 , 78 , 79 , 80 , 81 , 82 , 83 , 86 , 88 , 98 , 108 , 119 , 120 , 133 , 134 , 138 , 139 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 187 , 188 ) , phosphoamino acid analysis ( 188 ) , western blotting ( 4 , 5 , 9 , 11 , 12 , 13 , 17 , 19 , 20 , 42 , 45 , 46 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 57 , 70 , 79 , 80 , 81 , 82 , 83 , 86 , 88 , 98 , 108 , 119 , 120 , 133 , 134 , 138 , 141 , 142 , 144 , 145 , 146 , 147 , 149 , 150 , 151 , 152 , 153 , 157 , 158 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 176 , 177 , 181 , 182 , 184 , 185 , 187 )
Disease tissue studied:
breast cancer ( 12 , 147 ) , leukemia ( 24 , 75 , 76 , 77 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 ) , acute myelogenous leukemia ( 24 ) , chronic myelogenous leukemia ( 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 ) , liver cancer ( 153 ) , lung cancer ( 95 , 96 , 97 , 99 , 102 , 103 , 104 , 105 , 106 , 107 , 134 , 144 , 150 ) , non-small cell lung cancer ( 95 , 96 , 97 , 102 , 103 , 104 , 105 , 106 , 107 ) , lymphoma ( 11 , 52 ) , B cell lymphoma ( 11 ) , T cell lymphoma ( 52 ) , neuroblastoma ( 4 , 50 ) , pancreatic cancer ( 19 ) , melanoma skin cancer ( 12 ) , testicular cancer ( 60 ) , diabetes mellitus ( 153 ) , type 2 diabetes ( 153 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 3 , 15 ) , 'brain, hippocampus' ( 138 ) , 'kidney, inner medulla' ( 182 ) , 'neuron, cortical'-brain ( 155 , 180 ) , 'neuron, hippocampal, CA1 pyramidal'-brain ( 143 ) , 'neuron, substantia nigra' ( 4 ) , 'renal, podocyte' ( 55 ) , 'stem, embryonic' ( 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ) , 32D (myeloid) ( 78 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 159 , 177 , 187 ) , 3T3 (fibroblast) [Src (human)] ( 150 ) , 3T3 (fibroblast) ( 119 ) , A20 (B lymphocyte) ( 11 ) , A549 (pulmonary) ( 144 ) , aorta ( 88 ) , astrocyte-'brain, striatum' ( 155 ) , B lymphocyte ( 5 , 33 , 34 ) , B lymphocyte-spleen ( 57 , 162 ) , BAEC (endothelial) ( 161 ) , BaF3 ('B lymphocyte, precursor') [EGFR (human)] ( 150 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 2 ) , BaF3 ('B lymphocyte, precursor') ( 17 , 98 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 173 , 176 ) , beta TC6 (pancreatic) ( 19 ) , blood ( 24 ) , BMMC (mast) ( 54 ) , bone marrow ( 149 ) , brain ( 26 , 27 , 74 , 92 , 109 , 135 ) , C2C12 (myoblast) ( 42 , 90 , 148 ) , C2C12-D (muscle cell) ( 136 , 137 ) , CHO (fibroblast) ( 20 ) , chondrocyte ( 165 ) , COS (fibroblast) ( 17 , 175 , 178 , 188 ) , dendritic cell ( 119 ) , dendritic cell [MAPKAPK2 (mouse), homozygous knockout] ( 119 ) , dendritic cell [MSK1 (mouse), homozygous knockout] ( 119 ) , embryo ( 27 ) , endothelial-aorta ( 168 ) , F9 (testicular) ( 178 ) , Fao (hepatic) ( 153 ) , FL5.12 (lymphoid) ( 170 ) , GD25 (fibroblast) ( 172 ) , heart ( 16 , 73 , 91 , 93 , 100 , 121 , 131 , 146 ) , HEK293T (epithelial) ( 4 ) , HeLa (cervical) ( 51 ) , Hepa 1-6 (epithelial) ( 85 ) , hepatocyte-liver ( 156 ) , HepG2 (hepatic) ( 153 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 7 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 7 ) , HL-1 (myocyte) ( 7 ) , JB (epithelial) ( 183 ) , liver ( 14 , 22 , 27 , 71 , 72 , 83 , 94 , 101 , 122 , 127 , 128 , 129 , 130 , 132 , 140 , 153 ) , liver [Akt2 (mouse), homozygous knockout] ( 123 , 124 , 125 , 126 ) , liver [leptin (mouse), homozygous knockout] ( 22 ) , lung ( 89 , 95 , 96 , 97 , 134 , 166 ) , lung [EGFR (mouse), transgenic] ( 99 ) , macrophage-bone marrow ( 56 , 139 , 142 , 160 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 56 ) , macrophage-peritoneum ( 21 , 49 , 185 ) , mast-bone marrow ( 174 ) , mast-bone marrow [PTPRA (mouse), homozygous knockout] ( 86 ) , mast-bone marrow [SHP-2 (mouse), homozygous knockout] ( 70 ) , MCP-5 (mast) ( 110 ) , MEF (fibroblast) ( 12 , 18 , 51 , 120 , 144 , 146 , 151 , 152 , 161 , 169 ) , MEF (fibroblast) [LKB1 (mouse)] ( 171 ) , MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2] ( 181 ) , MEF (fibroblast) [P38A (mouse), homozygous knockout] ( 80 ) , MEF (fibroblast) [PKR (mouse), homozygous knockout] ( 53 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 18 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 18 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 44 ) , MH-S (macrophage) ( 20 ) , microglia ( 141 ) , mIMCD-3 (epithelial) ( 182 ) , mLEC (epithelial) ( 48 ) , mpkCCD (renal) ( 58 ) , myeloid ( 142 ) , myoblast ( 157 ) , myocyte-heart ( 146 , 158 , 184 ) , natural helper ( 13 ) , Neuro-2a (neuron) ( 50 ) , neuron-brain ( 23 ) , neutrophil ( 9 ) , osteoclast ( 142 ) , P19 (testicular) ( 60 ) , platelet-blood ( 88 ) , PYS-2 (epithelial) ( 61 ) , RAW 264 (macrophage) ( 164 ) , RAW 264.7 (macrophage) ( 6 , 75 , 76 , 77 , 81 ) , S49 (T lymphocyte) ( 52 ) , SH-SY5Y (neural crest) ( 4 ) , splenocyte ( 163 ) , stromal ( 46 ) , Swiss 3T3 (fibroblast) ( 167 ) , SYF (fibroblast) [Src (mouse), transfection] ( 25 ) , T lymphocyte [FOXO1A (mouse), transgenic] ( 45 ) , T lymphocyte-blood ( 163 ) , T lymphocyte-lymph node ( 79 , 133 ) , T lymphocyte-lymph node [P38A (mouse), genetic knockin] ( 82 ) , T lymphocyte-spleen ( 133 , 162 ) , T lymphocyte-spleen [P38A (mouse), genetic knockin] ( 82 ) , T47D (breast cell) ( 12 , 147 ) , thymocyte ( 5 ) , WEHI-3 (myeloid) ( 173 ) , WM2664 (melanocyte) ( 12 )

Upstream Regulation
Regulatory protein:
ADRB1 (mouse) ( 16 ) , Akt1 (mouse) ( 161 ) , BCR-ABL1 (human) ( 98 , 150 ) , DUSP19 (mouse) ( 175 ) , DUSP3 (mouse) ( 175 ) , FCER1A (mouse) ( 110 ) , FOXP1 (mouse) ( 45 ) , GADD45A (mouse) ( 133 ) , GCN2 (mouse) ( 12 ) , GRB10 (human) ( 17 ) , HSP90A (human) ( 161 ) , IFI16 (mouse) ( 108 ) , IGF1R (mouse) ( 170 ) , JAK2 (human) ( 176 ) , MAPKAPK2 (human) ( 184 ) , MAPKAPK2 (mouse) ( 119 ) , MAPKAPK3 (mouse) ( 119 ) , MKK6 (human) ( 42 , 43 ) , Mnk1 (mouse) ( 144 ) , Mnk2 (mouse) ( 144 ) , MSK1 (mouse) ( 181 ) , MSK2 (mouse) ( 181 ) , PERK (mouse) ( 12 ) , PKR (mouse) ( 12 ) , Plectin-1 (mouse) ( 157 ) , PTGER4 (mouse) ( 55 ) , Raptor (mouse) ( 18 ) , RICTOR (mouse) ( 18 ) , SH3BP2 (mouse) ( 142 ) , SHP-2 (mouse) ( 70 ) , SIGLEC7 (mouse) ( 9 ) , Src (human) ( 150 ) , TAK1 (mouse) ( 146 ) , Tel (human) ( 176 ) , TSC2 (mouse) ( 152 ) , UCP2 (mouse) ( 139 )
Kinases, in vitro:
MKK6 (human) ( 11 , 87 ) , P38A (human) ( 79 , 162 ) , P38A (mouse) ( 4 )
Putative upstream phosphatases:
PTP1B (mouse) ( 11 )
Phosphatases, in vitro:
DUSP10 (human) ( 87 ) , PPPM1A (human) ( 87 ) , PTP1B (human) ( 11 )
Treatments:
acadesine ( 171 ) , adriamycin ( 5 , 53 ) , alpha-lipoic_acid ( 50 ) , amino_acid_starvation ( 12 ) , anisomycin ( 119 , 181 , 185 ) , anti-CD3 ( 79 , 162 , 163 ) , anti-CD3/CD28 ( 45 , 82 , 133 ) , anti-IgE ( 70 ) , anti-IgM ( 57 , 162 , 186 ) , Aplidin ( 169 ) , arsenite ( 43 , 151 , 184 ) , bacterial infection ( 166 ) , benzo(a)pyrene ( 134 ) , BI-D1870 ( 119 ) , BIRB-0796 ( 119 ) , cAMP_analog ( 52 ) , cholera_toxin ( 52 ) , ciclopirox_olamine ( 48 ) , cold_water_stress ( 138 ) , colforsin ( 52 ) , ConA ( 83 , 163 ) , cyclic_stretch ( 55 ) , cytochalasin_D ( 148 ) , EGF ( 108 , 145 , 175 , 181 , 187 ) , ether ( 138 ) , fibrinogen ( 9 ) , food deprivation ( 138 ) , gefitinib ( 150 ) , genistein ( 155 ) , GLP-1 ( 19 ) , glucose ( 55 ) , guanosine ( 141 ) , H2O2 ( 55 , 144 , 161 ) , heat_shock ( 148 ) , heparin sodium ( 12 ) , hypertonic_buffer ( 159 ) , hypoxia ( 180 ) , IFN-alpha ( 98 ) , IFN-gamma ( 141 , 168 ) , IGF-1 ( 170 ) , IgG ( 160 ) , IL-2 ( 13 ) , IL-25 ( 13 ) , IL-3 ( 173 , 176 ) , IL-33 ( 6 , 13 ) , imatinib ( 4 , 78 , 178 ) , insulin ( 15 ) , ionizing_radiation ( 20 ) , licochalcone_A ( 81 ) , licochalcone_B ( 81 ) , licochalcone_C ( 81 ) , licochalcone_D ( 81 ) , LIF ( 154 ) , low_glucose ( 55 ) , LPS ( 49 , 56 , 81 , 119 , 139 , 160 , 168 ) , LY294002 ( 15 , 178 ) , M-CSF ( 142 , 149 ) , midazolam ( 158 ) , MK-2206 ( 15 ) , MMS ( 152 ) , MPTP ( 4 ) , muramyl_dipeptide ( 46 ) , NBNI ( 155 ) , norepinephrine ( 52 ) , NTCU ( 134 ) , okadaic_acid ( 150 , 185 ) , osmotic_stress ( 167 , 182 ) , palmitate ( 120 ) , Pam3CSK4 ( 119 ) , PAR1-activating_peptide ( 174 ) , PD169316 ( 183 ) , PD184352 ( 119 ) , PD98059 ( 183 ) , PGE2 ( 54 , 55 , 164 ) , phorbol_ester ( 79 , 119 , 181 , 185 ) , pomegranate_wine ( 134 ) , PP2 ( 163 , 170 ) , PTX ( 52 ) , RANKL ( 149 , 164 ) , rapamycin ( 43 , 54 ) , retinoic_acid ( 178 ) , SB202190 ( 50 , 78 , 145 , 156 , 167 , 168 , 179 , 182 , 183 ) , SB203580 ( 13 , 119 , 158 , 162 , 167 , 184 ) , SB239063 ( 119 ) , SCF ( 84 , 86 , 174 ) , SL0101 ( 119 ) , SNP ( 165 ) , somatostatin ( 52 ) , sorbitol ( 175 , 184 , 187 ) , SP600125 ( 170 ) , streptozotocin ( 153 ) , SU6656 ( 150 ) , swim stress ( 23 ) , thapsigargin ( 12 ) , thrombin ( 88 , 158 , 174 ) , TNF ( 80 , 119 , 141 , 148 , 149 ) , Torin1 ( 54 ) , U50488 ( 155 ) , UV ( 167 , 177 , 179 , 181 , 183 , 188 ) , vinblastine ( 148 ) , wortmannin ( 54 , 178 ) , zymosan ( 185 )

Downstream Regulation
Effects of modification on P38A:
enzymatic activity, induced ( 42 , 79 , 87 , 155 , 159 , 178 ) , molecular association, regulation ( 165 ) , phosphorylation ( 4 )
Effects of modification on biological processes:
transcription, altered ( 185 )
Induce interaction with:
PKCZ (mouse) ( 165 )

References 

1

Fabrik I, et al. (2018) The Early Dendritic Cell Signaling Induced by Virulent Francisella tularensis Strain Occurs in Phases and Involves the Activation of Extracellular Signal-Regulated Kinases (ERKs) and p38 In the Later Stage. Mol Cell Proteomics 17, 81-94
29046388   Curated Info

2

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

3

Minard AY, et al. (2016) mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep 17, 29-36
27681418   Curated Info

4

Wu R, et al. (2016) c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death. Cell Death Differ 23, 542-52
26517532   Curated Info

5

Thornton TM, et al. (2016) Inactivation of nuclear GSK3β by Ser(389) phosphorylation promotes lymphocyte fitness during DNA double-strand break response. Nat Commun 7, 10553
26822034   Curated Info

6

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

7

Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45
25162660   Curated Info

8

Crocetti J, et al. (2014) Selective Phosphorylation of the Dlg1AB Variant Is Critical for TCR-Induced p38 Activation and Induction of Proinflammatory Cytokines in CD8+ T Cells. J Immunol 193, 2651-60
25098293   Curated Info

9

McMillan SJ, et al. (2014) Siglec-E Promotes β2-Integrin-dependent NADPH Oxidase Activation to Suppress Neutrophil Recruitment to the Lung. J Biol Chem 289, 20370-6
24895121   Curated Info

10

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

11

Medgyesi D, et al. (2014) The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med 211, 427-40
24590766   Curated Info

12

Bhattacharya S, et al. (2013) Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene 32, 4214-21
23045272   Curated Info

13

Furusawa J, et al. (2013) Critical role of p38 and GATA3 in natural helper cell function. J Immunol 191, 1818-26
23851685   Curated Info

14

Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750   Curated Info

15

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

16

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

17

Kazi JU, Rönnstrand L (2013) FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol 7, 402-18
23246379   Curated Info

18

Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3
23429704   Curated Info

19

Zhou G, et al. (2013) p38 MAP Kinase Interacts with and Stabilizes Pancreatic and Duodenal Homeobox-1. Curr Mol Med 13, 377-86
23331010   Curated Info

20

Ray D, et al. (2013) Tristetraprolin Mediates Radiation-Induced TNF-α Production in Lung Macrophages. PLoS One 8, e57290
23468959   Curated Info

21

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

22

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

23

Lemos JC, et al. (2012) Repeated stress dysregulates κ-opioid receptor signaling in the dorsal raphe through a p38α MAPK-dependent mechanism. J Neurosci 32, 12325-36
22956823   Curated Info

24

Trost M, et al. (2012) Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood 120, e17-27
22802335   Curated Info

25

Ferrando IM, et al. (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11, 355-69
22499769   Curated Info

26

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

27

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

28

Ren H (2011) CST Curation Set: 12902; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Ren H (2011) CST Curation Set: 12903; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Ren H (2011) CST Curation Set: 12904; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Ren H (2011) CST Curation Set: 12905; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Ren H (2011) CST Curation Set: 12906; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Ren H (2011) CST Curation Set: 12893; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Ren H (2011) CST Curation Set: 12894; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Ren H (2011) CST Curation Set: 12895; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Ren H (2011) CST Curation Set: 12896; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Ren H (2011) CST Curation Set: 12897; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

38

Ren H (2011) CST Curation Set: 12898; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

39

Ren H (2011) CST Curation Set: 12900; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

40

Ren H (2011) CST Curation Set: 12901; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

41

Chaturvedi A, et al. (2011) Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments. Nat Immunol 12, 1119-26
21964606   Curated Info

42

Zhang G, Jin B, Li YP (2011) C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J 30, 4323-35
21847090   Curated Info

43

Wu XN, et al. (2011) Phosphorylation of Raptor by p38beta participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation. J Biol Chem 286, 31501-11
21757713   Curated Info

44

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

45

Feng X, et al. (2011) Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 12, 544-50
21532575   Curated Info

46

Kim YG, et al. (2011) The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 34, 769-80
21565531   Curated Info

47

Bard-Chapeau EA, et al. (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629-39
21575863   Curated Info

48

Luo Y, et al. (2011) The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene 30, 2098-107
21217783   Curated Info

49

Liu X, et al. (2011) Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 12, 416-24
21441935   Curated Info

50

Wang X, et al. (2011) Essential role of ERK activation in neurite outgrowth induced by α-lipoic acid. Biochim Biophys Acta 1813, 827-38
21295083   Curated Info

51

Ronkina N, et al. (2011) Stress induced gene expression: a direct role for MAPKAP kinases in transcriptional activation of immediate early genes. Nucleic Acids Res 39, 2503-18
21109534   Curated Info

52

Lajevic MD, Suleiman S, Cohen RL, Chambers DA (2011) Activation of p38 mitogen-activated protein kinase by norepinephrine in T-lineage cells. Immunology 132, 197-208
21039464   Curated Info

53

Peidis P, et al. (2011) Doxorubicin bypasses the cytoprotective effects of eIF2α phosphorylation and promotes PKR-mediated cell death. Cell Death Differ 18, 145-54
20559319   Curated Info

54

Kuehn HS, et al. (2011) Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 286, 391-402
20980255   Curated Info

55

Faour WH, Thibodeau JF, Kennedy CR (2010) Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes. Cell Signal 22, 1222-30
20362052   Curated Info

56

Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371
20531401   Curated Info

57

Damdinsuren B, et al. (2010) Single round of antigen receptor signaling programs naive B cells to receive T cell help. Immunity 32, 355-66
20226693   Curated Info

58

Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7
20139300   Curated Info

59

Zhou J (2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

60

Zhou J (2010) CST Curation Set: 9109; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

61

Zhou J (2010) CST Curation Set: 9108; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

62

Tucker M (2009) CST Curation Set: 8089; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Tucker M (2009) CST Curation Set: 8084; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

64

Tucker M (2009) CST Curation Set: 8081; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

65

Tucker M (2009) CST Curation Set: 8088; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

66

Tucker M (2009) CST Curation Set: 8077; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

67

Tucker M (2009) CST Curation Set: 8085; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

68

Tucker M (2009) CST Curation Set: 8080; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

69

Tucker M (2009) CST Curation Set: 8072; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

70

McPherson VA, et al. (2009) SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc(epsilon)RI-induced activation of Fyn and Erk pathways leading to TNF(alpha) release from bone marrow-derived mast cells. J Immunol 183, 4940-7
19786542   Curated Info

71

Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

72

Zhou J (2009) CST Curation Set: 7425; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

73

Zhou J (2009) CST Curation Set: 7418; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

74

Zhou J (2009) CST Curation Set: 7383; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

75

Possemato A (2009) CST Curation Set: 7168; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Possemato A (2009) CST Curation Set: 7167; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Possemato A (2009) CST Curation Set: 7166; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/control; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Mancini M, et al. (2009) 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Traffic 10, 637-47
19220809   Curated Info

79

Mittelstadt PR, Yamaguchi H, Appella E, Ashwell JD (2009) T cell receptor-mediated activation of p38{alpha} by mono-phosphorylation of the activation loop results in altered substrate specificity. J Biol Chem 284, 15469-74
19324872   Curated Info

80

Chew J, et al. (2009) WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol 11, 659-66
19377466   Curated Info

81

Furusawa J, et al. (2009) Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol 9, 499-507
19291859   Curated Info

82

Jirmanova L, et al. (2009) Genetic disruption of p38alpha Tyr323 phosphorylation prevents T-cell receptor-mediated p38alpha activation and impairs interferon-gamma production. Blood 113, 2229-37
19011223   Curated Info

83

Das M, et al. (2009) Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136, 249-60
19167327   Curated Info

84

Simon C, et al. (2008) Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112, 4039-47
18753636   Curated Info

85

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

86

Samayawardhena LA, Pallen CJ (2008) Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283, 29175-85
18725415   Curated Info

87

Zhang YY, Mei ZQ, Wu JW, Wang ZX (2008) Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphorylation states. J Biol Chem 283, 26591-601
18669639   Curated Info

88

Gambaryan S, et al. (2008) NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost 6, 1376-84
18485089   Curated Info

89

Rikova K (2008) CST Curation Set: 4985; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Possemato A (2008) CST Curation Set: 4934; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Stokes M (2008) CST Curation Set: 4845; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

92

Zhou J (2008) CST Curation Set: 4859; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

93

Zhou J (2008) CST Curation Set: 4782; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

94

Zhou J (2008) CST Curation Set: 4783; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

95

Rikova K (2008) CST Curation Set: 4438; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

96

Rikova K (2008) CST Curation Set: 4439; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Rikova K (2008) CST Curation Set: 4440; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Katsoulidis E, et al. (2008) Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem 283, 10793-803
18287094   Curated Info

99

Ren H (2008) CST Curation Set: 4335; Year: 2008; Biosample/Treatment: cell line, EGFR_WT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Zhou J (2008) CST Curation Set: 4324; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

101

Zhou J (2008) CST Curation Set: 4325; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

102

Rikova K (2008) CST Curation Set: 4249; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Rikova K (2008) CST Curation Set: 4250; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Rikova K (2008) CST Curation Set: 4251; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Rikova K (2008) CST Curation Set: 4252; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Rikova K (2008) CST Curation Set: 4253; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

107

Rikova K (2008) CST Curation Set: 4254; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Ding B, Lengyel P (2008) p204 protein is a novel modulator of ras activity. J Biol Chem 283, 5831-48
18165224   Curated Info

109

Ballif BA, Carey GR, Sunyaev SR, Gygi SP (2008) Large-scale identification and evolution indexing of tyrosine phosphorylation sites from murine brain. J Proteome Res 7, 311-8
18034455   Curated Info

110

Cao L, et al. (2007) Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol 179, 5864-76
17947660   Curated Info

111

Gu T (2007) CST Curation Set: 3402; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

112

Gu T (2007) CST Curation Set: 3403; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

113

Gu T (2007) CST Curation Set: 3404; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Gu T (2007) CST Curation Set: 3405; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Gu T (2007) CST Curation Set: 3406; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

116

Gu T (2007) CST Curation Set: 3407; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Gu T (2007) CST Curation Set: 3408; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3 (D835Y))/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

118

Gu T (2007) CST Curation Set: 3409; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3 (D835Y))/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

Zaru R, et al. (2007) The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat Immunol 8, 1227-35
17906627   Curated Info

120

Jaeschke A, Davis RJ (2007) Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 27, 498-508
17679097   Curated Info

121

Guo A (2007) CST Curation Set: 3118; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS*/T*F/Y) Immunoaffinity Beads Cat#: 1992
Curated Info

122

Guo A (2007) CST Curation Set: 3119; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS*/T*F/Y) Immunoaffinity Beads Cat#: 1992
Curated Info

123

Guo A (2007) CST Curation Set: 2987; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

124

Guo A (2007) CST Curation Set: 2988; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

125

Guo A (2007) CST Curation Set: 2989; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

126

Guo A (2007) CST Curation Set: 2990; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

127

Guo A (2007) CST Curation Set: 2983; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

128

Guo A (2007) CST Curation Set: 2984; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

129

Guo A (2007) CST Curation Set: 2985; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

130

Guo A (2007) CST Curation Set: 2986; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

131

Guo A (2007) CST Curation Set: 2827; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

132

Guo A (2007) CST Curation Set: 2830; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

133

Jirmanova L, Jankovic D, Fornace AJ, Ashwell JD (2007) Gadd45alpha regulates p38-dependent dendritic cell cytokine production and Th1 differentiation. J Immunol 178, 4153-8
17371971   Curated Info

134

Khan N, et al. (2007) Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 67, 3475-82
17389758   Curated Info

135

Guo A (2007) CST Curation Set: 2675; Year: 2007; Biosample/Treatment: tissue, brain/LY; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

136

Guo A (2007) CST Curation Set: 2564; Year: 2007; Biosample/Treatment: cell line, C2C12-D/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

137

Guo A (2007) CST Curation Set: 2565; Year: 2007; Biosample/Treatment: cell line, C2C12-D/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

138

Ikeda Y, Ishiguro K, Fujita SC (2007) Ether stress-induced Alzheimer-like tau phosphorylation in the normal mouse brain. FEBS Lett 581, 891-7
17289030   Curated Info

139

Emre Y, et al. (2007) Mitochondria contribute to LPS-induced MAPK activation via uncoupling protein UCP2 in macrophages. Biochem J 402, 271-8
17073824   Curated Info

140

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info

141

D'Alimonte I, et al. (2007) Guanosine inhibits CD40 receptor expression and function induced by cytokines and beta amyloid in mouse microglia cells. J Immunol 178, 720-31
17202332   Curated Info

142

Ueki Y, et al. (2007) Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 128, 71-83
17218256   Curated Info

143

Sindreu CB, Scheiner ZS, Storm DR (2007) Ca2+ -stimulated adenylyl cyclases regulate ERK-dependent activation of MSK1 during fear conditioning. Neuron 53, 79-89
17196532   Curated Info

144

Shenberger JS, et al. (2007) Roles of mitogen-activated protein kinase signal-integrating kinases 1 and 2 in oxidant-mediated eIF4E phosphorylation. Int J Biochem Cell Biol 39, 1828-42
17689282   Curated Info

145

Frey MR, Dise RS, Edelblum KL, Polk DB (2006) p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 25, 5683-92
17139251   Curated Info

146

Xie M, et al. (2006) A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 103, 17378-83
17085580   Curated Info

147

Vicent GP, et al. (2006) Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. Mol Cell 24, 367-81
17081988   Curated Info

148

Launay N, et al. (2006) Cell signaling pathways to alphaB-crystallin following stresses of the cytoskeleton. Exp Cell Res 312, 3570-84
16979163   Curated Info

149

Huang H, et al. (2006) Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. Cell Death Differ 13, 1879-91
16498455   Curated Info

150

Sharma SV, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-35
17097564   Curated Info

151

Vertii A, Hakim C, Kotlyarov A, Gaestel M (2006) Analysis of properties of small heat shock protein Hsp25 in MAPK-activated protein kinase 2 (MK2)-deficient cells: MK2-dependent insolubilization of Hsp25 oligomers correlates with susceptibility to stress. J Biol Chem 281, 26966-75
16840785   Curated Info

152

Ghosh S, et al. (2006) Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 10, 215-26
16959613   Curated Info

153

Qiao L, MacDougald OA, Shao J (2006) CCAAT/enhancer-binding protein alpha mediates induction of hepatic phosphoenolpyruvate carboxykinase by p38 mitogen-activated protein kinase. J Biol Chem 281, 24390-7
16807249   Curated Info

154

Lee ER, McCool KW, Murdoch FE, Fritsch MK (2006) Dynamic changes in histone H3 phosphoacetylation during early embryonic stem cell differentiation are directly mediated by mitogen- and stress-activated protein kinase 1 via activation of MAPK pathways. J Biol Chem 281, 21162-72
16728397   Curated Info

155

Bruchas MR, Macey TA, Lowe JD, Chavkin C (2006) Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281, 18081-9
16648139   Curated Info

156

Nan L, et al. (2006) Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol 80, 228-40
16563375   Curated Info

157

Gregor M, et al. (2006) Plectin scaffolds recruit energy-controlling AMP-activated protein kinase (AMPK) in differentiated myofibres. J Cell Sci 119, 1864-75
16608880   Curated Info

158

Tanabe K, et al. (2005) Midazolam suppresses thrombin-induced heat shock protein 27 phosphorylation through inhibition of p38 mitogen-activated protein kinase in cardiac myocytes. J Cell Biochem 96, 56-64
16052527   Curated Info

159

Friis MB, et al. (2005) Cell shrinkage as a signal to apoptosis in NIH 3T3 fibroblasts. J Physiol 567, 427-43
15975986   Curated Info

160

Lucas M, Zhang X, Prasanna V, Mosser DM (2005) ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 175, 469-77
15972681   Curated Info

161

Zhang R, et al. (2005) Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24, 3954-63
15782121   Curated Info

162

Salvador JM, et al. (2005) Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 6, 390-5
15735648   Curated Info

163

Salvador JM, et al. (2005) The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat Immunol 6, 396-402
15735649   Curated Info

164

Kobayashi Y, et al. (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 280, 11395-403
15647289   Curated Info

165

Kim JS, et al. (2005) p38 kinase mediates nitric oxide-induced apoptosis of chondrocytes through the inhibition of protein kinase C zeta by blocking autophosphorylation. Cell Death Differ 12, 201-12
15665819   Curated Info

166

Schmeck B, et al. (2004) Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem 279, 53241-7
15485852   Curated Info

167

Lunn JA, Rozengurt E (2004) Hyperosmotic stress induces rapid focal adhesion kinase phosphorylation at tyrosines 397 and 577. Role of Src family kinases and Rho family GTPases. J Biol Chem 279, 45266-78
15302877   Curated Info

168

Huang H, Rose JL, Hoyt DG (2004) p38 Mitogen-activated protein kinase mediates synergistic induction of inducible nitric-oxide synthase by lipopolysaccharide and interferon-gamma through signal transducer and activator of transcription 1 Ser727 phosphorylation in murine aortic endothelial cells. Mol Pharmacol 66, 302-11
15266021   Curated Info

169

Cuadrado A, et al. (2004) JNK activation is critical for Aplidin-induced apoptosis. Oncogene 23, 4673-80
15122339   Curated Info

170

Leahy M, Lyons A, Krause D, O'Connor R (2004) Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251. J Biol Chem 279, 18306-13
14963047   Curated Info

171

Shaw RJ, et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101, 3329-35
14985505   Curated Info

172

Pankov R, et al. (2003) Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J Biol Chem 278, 18671-81
12637511   Curated Info

173

Wang JM, Lai MZ, Yang-Yen HF (2003) Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol Cell Biol 23, 1896-909
12612065   Curated Info

174

Vliagoftis H (2002) Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1. J Immunol 169, 4551-8
12370392   Curated Info

175

Nakamura K, et al. (2002) A novel low-molecular-mass dual-specificity phosphatase, LDP-2, with a naturally occurring substitution that affects substrate specificity. J Biochem (Tokyo) 132, 463-70
12204117   Curated Info

176

Ho JM, et al. (2002) TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 100, 1438-48
12149229   Curated Info

177

Deng J, et al. (2002) Activation of GCN2 in UV-irradiated cells inhibits translation. Curr Biol 12, 1279-86
12176355   Curated Info

178

Gianni M, et al. (2002) Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2. J Biol Chem 277, 24859-62
12032135   Curated Info

179

She QB, Ma WY, Zhong S, Dong Z (2002) Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J Biol Chem 277, 24039-48
11983683   Curated Info

180

Zhu Y, et al. (2002) p38 Mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J Biol Chem 277, 22909-14
11948180   Curated Info

181

Wiggin GR, et al. (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22, 2871-81
11909979   Curated Info

182

Dmitrieva NI, Bulavin DV, Fornace AJ, Burg MB (2002) Rapid activation of G2/M checkpoint after hypertonic stress in renal inner medullary epithelial (IME) cells is protective and requires p38 kinase. Proc Natl Acad Sci U S A 99, 184-9
11756692   Curated Info

183

Zhang Y, et al. (2001) UVA induces Ser381 phosphorylation of p90RSK/MAPKAP-K1 via ERK and JNK pathways. J Biol Chem 276, 14572-80
11278279   Curated Info

184

Hoover HE, Thuerauf DJ, Martindale JJ, Glembotski CC (2000) alpha B-crystallin gene induction and phosphorylation by MKK6-activated p38. A potential role for alpha B-crystallin as a target of the p38 branch of the cardiac stress response. J Biol Chem 275, 23825-33
10816593   Curated Info

185

Gijón MA, et al. (2000) Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J Biol Chem 275, 20146-56
10867029   Curated Info

186

Swart JM, Bergeron DM, Chiles TC (2000) Identification of a membrane Ig-induced p38 mitogen-activated protein kinase module that regulates cAMP response element binding protein phosphorylation and transcriptional activation in CH31 B cell lymphomas. J Immunol 164, 2311-9
10679065   Curated Info

187

Xing J, et al. (1998) Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol Cell Biol 18, 1946-55
9528766   Curated Info

188

Raingeaud J, et al. (1995) Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270, 7420-6
7535770   Curated Info